Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast  | Oncotarget
Channel: Oncotarget
Date: 2023-05-01

Oncotarget published this research perspective on April 24, 2023 in Volume 14, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast" by Dr. Georg F. Weber from the University of Cincinnati Academic Health Center, Cincinnati, OH.
@UniversityofCincinnati 
#breastcancer  #openaccess   #cancer   #research   #biomarkers  #biopsy  #mammography  #openscience   #peerreview   #journal   #publication   #perspective   #oncologyresearch  

DOI - https://doi.org/10.18632/oncotarget.28402

Correspondence to - Georg F. Weber - georg.weber@uc.edu

Abstract

Premalignant lesions in the breast pose a difficult decision-making problem, whether to treat proactively and accept the side effects or to engage in watchful waiting and possibly encounter a later diagnosis of invasive cancer. A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system. The gene products of tumor progression may be expressed in early non-cancerous (“premalignant”) lesions, where they are associated with a high probability for full transformation in breast cancers. One such molecule is the OPN splice variant-c. OPN-c is also present in a fraction of the premalignant lesions, where it reflects an elevated risk for progression to cancer within 5 years, regardless of the lesion’s subtype. This marker has the properties needed to facilitate decisions to treat at the premalignant stage.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28402

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - breast cancer premalignant lesion, biomarker, biopsy, mammography

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957